Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: Long-term results

Leukemia and Lymphoma

Volumn 50, Issue 1, 2009, Pages 114-118

  Palandri, Francesca ^a   Testoni, Nicoletta ^a   Luatti, Simona ^a   Marzocchi, Giulia ^a   Baldazzi, Carmen ^a   Stacchini, Monica ^a   Castagnetti, Fausto ^a   Breccia, Massimo ^b   Specchia, Giorgina ^c   Pane, Fabrizio ^d   Saglio, Giuseppe ^e   Martinelli, Giovanni ^a   Baccarani, Michele ^a   Rosti, Gianantonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME DISORDER; CHROMOSOME DUPLICATION; CHROMOSOME LOSS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; Y CHROMOSOME;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; NEOPLASM STAGING; PIPERAZINES; PYRIMIDINES; SURVIVAL RATE; TIME FACTORS; TRISOMY;

EID: 59249094911     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802492415     Document Type: Article

References (18)

1. Nowell, P. C. and Hungerford, D. A. (1960) A minute chromosome in human chronic granulocytic leukemia. Science, 132, pp. 1497-1501.
2. Kelliher, M., McLaughlin, J., Witte, O. and Rosenberg, N. (1990) Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc Natl Acad Sci USA, 87, pp. 6649-6653.
3. Druker, B. J., Talpaz, M., Resta, D. J., Reese, S. F., Ford, J. M. Capdeville, R. et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344, pp. 1031-1037.
4. Marktel, S., Marin, D., Foot, N., Szydlo, R., Bua, M. Karadimitris, A. et al. (2003) Chronic myeloid leukaemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica, 88, pp. 260-267.
5. Sokal, J. E., Gomez, G. A., Baccarani, M., Tura, S., Clarkson, B. D. Cervantes, F. et al. (1988) Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood, 72, pp. 294-298.
6. Kantarjian, H. M., Smith, T. L., McCredie, K. B., Keating, M. J., Walters, R. S. Talpaz, M. et al. (1985) Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood, 66, pp. 1326-1335.
7. Rosti, G., Martinelli, G., Bassi, S., Amabile, M., Trabacchi, E. Giannini, B. et al. (2004) Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood, 103, pp. 2284-2290.
8. Palandri, F., Iacobucci, I., Martinelli, G., Amabile, M., Poerio, A. Testoni, N. et al. (2008) for the GIMEMA Working Party on CML. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA Working Party on CML. J Clin Oncol, 26, pp. 106-111.
9. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
10. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R. Howard, S. V. et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer, 35, pp. 1-39.
11. O'Dwyer, M. E., Mauro, M. J., Blasdel, C., Farnsworth, M., Kurilik, G. Hsieh, Y. C. et al. (2004) Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood, 103, p. 451.
12. Schoch, C., Haferlach, T., Kern, W., Schnittger, S., Berger, U. Hehlmann, R. et al. (2003) Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia, 17, pp. 461-463.
13. Cortes, J., Talpaz, M., Giles, F., O'Brien, S., Rios, M. B. Shan, J. et al. (2003) Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib therapy. Blood, 101, pp. 3794-3800.
14. Johansson, B., Fioretos, T. and Mitelman, F. (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol, 107, pp. 76-94.
15. Marktel, S., Marin, D., Foot, N., Szydlo, R., Bua, M. Karadimitris, A. et al. (2003) Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica, 88, pp. 260-267.
16. Deininger, M. W. (2003) Cytogenetic studies in patients on imatinib. Semin Hematol, 40:2, pp. 50-55.
17. Gambacorti-Passerini, C., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R. and Scapozza, L. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol, 4, pp. 75-85.
18. Baccarani, M., Saglio, G., Goldman, J., Hochhaus, A., Simonsson, B. Appelbaum, F. et al. (2006) Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 108, pp. 1809-1820.